a.sorensen
TL2 Moderator · Plovdiv
Contributes reviews on supplier material. Based in Plovdiv.
Joined 28 September 2024 · last posted 1d
74 posts, newest first. Showing up to 150.
-
Coming back to: Why I now write the concentration on the vial in marker Replied, post #13 · Practice › Reconstitution · 27 Jul 2026 · 2 likes post #12 answers the question as asked. The question underneath it is different. Foaming during reconstitution: bubbles in the solution are usually just air…
-
Immortal time bias in a claims-database study — one year on Replied, post #43 · Evidence › Study critique · 25 Jul 2026 · 8 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #89 · Compounds › Retatrutide · 24 Jul 2026 · 24 likes Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #99 · Access › International · 22 Jul 2026 · 0 likes Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is…
-
Documenting a supplier's response to a discrepancy Replied, post #42 · Sourcing › Vendor reports · 19 Jul 2026 · 6 likes Coming back to post #40, because the follow-up matters more than the original answer. Having read the exchange above, I think I was wrong earlier in this topic and I…
-
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #116 · Evidence › Journal club · 18 Jul 2026 · 17 likes PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy. Non-inferiority for safety was met. The trial was not designed to…
-
What a certificate commits its issuer to Replied, post #40 · Analytics › COA interpretation · 16 Jul 2026 · 0 likes Worth separating two things that post #36 runs together. Counter-ion form is crucial: peptides are isolated as salts, most often trifluoroacetate from reversed-phase…
-
Osteoarthritis and mechanical versus metabolic improvement — one year on Replied, post #12 · Clinical › Comorbidities · 9 Jul 2026 · 15 likes Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #10 · Access › Insurance & coverage · 8 Jul 2026 · 3 likes On post #6 — agreed on the reasoning, with one qualification. Tier placement and step therapy: some formularies place a medication on a higher tier or require you to…
-
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #76 · Evidence › Journal club · 2 Jul 2026 · 0 likes SURMOUNT-1 (N Engl J Med 2022): Tirzepatide obesity trial. The largest mean weight reduction for a pharmacological intervention at publication. Read the categorical…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #44 · Start Here › Welcome · 26 Jun 2026 · 12 likes The moderation log is public. Every staff action is logged with the rule cited and the reasoning stated. If you get moderated, the explanation is there and it is worth…
-
Asking a follow-up: new topic or new reply? Replied, post #10 · Start Here › How to Ask · 14 Jun 2026 · 7 likes On post #6 — agreed on the reasoning, with one qualification. Questions you cannot explain: "I cannot say why I am asking this, but is this compound stable at room…
-
Injecting into an area that has become firm: why not to Replied, post #51 · Practice › Administration · 11 Jun 2026 · 0 likes Air bubbles in a subcutaneous injection: the honest risk assessment is low. Tiny air bubbles in subcutaneous tissue do not behave like an air embolism in a blood…
-
Preservatives: function, testing, and limits — one year on Replied, post #21 · Pharmacology › Formulation chemistry · 3 Jun 2026 · 31 likes post #20 is right about the mechanism and I think understates the practical bit. I disagree with the reply above, and I think the disagreement is substantive rather…
-
Personal or family history of medullary thyroid carcinoma — what changed since Replied, post #55 · Safety › Contraindications · 30 May 2026 · 19 likes Medullary thyroid carcinoma (personal or family history) or multiple endocrine neoplasia type 2: absolute contraindication. The rodent preclinical signal is real enough…
-
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #89 · Compounds › Tirzepatide · 25 May 2026 · 31 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Replied, post #37 · Compounds › Semaglutide · 24 May 2026 · 21 likes Coming back to post #35, because the follow-up matters more than the original answer. The 165 to 184 hour range: that is roughly 7 to 7.6 days, which is why the weekly…
-
Citation sweep results: how many references did not say what was claimed Replied, post #99 · Meta › Wiki maintenance · 21 May 2026 · 27 likes Outdated external links: if a maintained page links to external sources and those links are broken or pages have moved, reporting that helps keep the page current.
-
Why fasting instructions for oral semaglutide are not optional advice Replied, post #5 · Compounds › Oral incretins · 16 May 2026 · 0 likes Oral versus injectable exposure: comparing a 14 mg oral dose with a 0.5 mg injectable dose is comparing apples to a different fruit. The oral bioavailability is low…
-
Revisiting: What pooling buys you and what it destroys Replied, post #23 · Evidence › Meta-analyses · 15 May 2026 · 13 likes Picking up post #20: that is the part I would want checked first. Number needed to treat from a meta-analysis: can be computed from the pooled estimate if the baseline…
-
[2026 update] 0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #118 · Devices › Syringes & needles · 14 May 2026 · 16 likes Dead volume: residual liquid in the hub and needle after withdrawal. Typical residual is 0.01 to 0.02 mL for an insulin syringe with a fixed needle. Accounting for it…
-
Journal club: LEADER as the historical anchor Replied, post #70 · Evidence › Journal club · 6 May 2026 · 0 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Whether an aggregate is worth publishing at all: a disputed topic — does this still hold? Replied, post #16 · Data & Tools › Datasets · 30 Apr 2026 · 14 likes Worth separating two things that post #12 runs together. How to contribute: if you have longitudinal data you want to add, the format is simple: date, measurement,…
-
Reading U-100 graduations, with a conversion table — one year on Replied, post #7 · Devices › Syringes & needles · 26 Mar 2026 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Reading U-100 graduations, with a conversion table Replied, post #14 · Devices › Syringes & needles · 2 Mar 2026 · 2 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Stepping down deliberately, and how to do it without losing progress Replied, post #58 · Practice › Dosing & titration · 14 Feb 2026 · 1 like Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Publication bias detection and its low power — does this still hold? Replied, post #11 · Evidence › Meta-analyses · 9 Feb 2026 · 0 likes Study quality and weighting: some meta-analyses weight all studies equally; others weight by study size or study quality. The choice affects the result and should be…
-
Shoulders, tangent skims, and defensible integration — the long version Replied, post #11 · Analytics › HPLC & UHPLC · 3 Feb 2026 · 1 like post #10 is right about the mechanism and I think understates the practical bit. Column chemistry and particle size: smaller particles (1.7 μm) give better resolution…
-
When to stop reading forums, including this one Replied, post #84 · Wellbeing › Mental health · 2 Feb 2026 · 1 like post #83 is right about the mechanism and I think understates the practical bit. Body image and weight loss: large weight loss changes a person's relationship with…
-
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Replied, post #125 · Compounds › Oral incretins · 2 Jan 2026 · 17 likes Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure…
-
"Greater than or equal to 99%" as a specification rather than a result Replied, post #97 · Analytics › COA interpretation · 25 Dec 2025 · 8 likes When a document puts the specification in the result column, it has told you the release criterion, not the measurement. Those are different claims and the second is…
-
What "marked as solution" means and who gets to mark it — does this still hold? Replied, post #21 · Start Here › Welcome · 16 Dec 2025 · 11 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Tracking a preprint to publication: a worked example Replied, post #128 · Evidence › Preprints · 13 Dec 2025 · 8 likes How to cite a preprint: author last name, first initial, et al. Title. Server name [preprint]. Posted date. Doi. Include the server name and note that it is a preprint.
-
Follow-up: The decimal-point error, and the habit that catches it Replied, post #116 · Practice › Reconstitution · 9 Dec 2025 · 2 likes Worth separating two things that post #112 runs together. The decimal-point error: computing 5 mg / 2 mL as 0.25 mg/mL instead of 2.5 mg/mL is the most common…
-
Tracking that stops updating and then resumes — the long version Replied, post #32 · Sourcing › Logistics · 31 Oct 2025 · 3 likes Declaring contents accurately: declaring accurately reduces intervention risk. A declaration of "peptide research chemical, 5 grams" is better than "vitamin" or "other"…
-
Power cut for eleven hours: how I assessed it afterwards Replied, post #106 · Practice › Storage & stability · 22 Oct 2025 · 0 likes post #105 answers the question as asked. The question underneath it is different. Visual inspection: if a solution is visibly cloudy, discoloured, or contains…
-
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Replied, post #34 · Compounds › Tirzepatide · 20 Oct 2025 · 0 likes SURMOUNT-OSA is notable because it used an objective physiological endpoint, the apnoea-hypopnoea index, rather than a symptom scale. Two parallel trials, with and…
-
What happens after your first post: likes, trust levels, and why none of it matters much… Replied, post #56 · Start Here › Welcome · 17 Oct 2025 · 6 likes The FAQ link in the sidebar is maintained and worth ten hours of forum browsing. It is not comprehensive but it is well indexed for the questions that come up most.
-
Reconciling a supplier certificate with an independent result Replied, post #7 · Sourcing › Vendor reports · 16 Oct 2025 · 16 likes On post #3 — agreed on the reasoning, with one qualification. Multiple services on one lot: agreement across two independent laboratories is stronger than a high number…
-
MHRA statements, read directly Replied, post #10 · Regional › UK & Ireland · 2 Oct 2025 · 24 likes Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with…
-
Compounds this community declines to help with, and why Replied, post #30 · Compounds › Other compounds · 29 Sep 2025 · 23 likes Picking up post #27: that is the part I would want checked first. How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data…
-
Payment method and the leverage it gives you, ranked Replied, post #25 · Sourcing › Payments · 17 Sep 2025 · 28 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Follow-up: The decimal-point error, and the habit that catches it Replied, post #53 · Practice › Reconstitution · 3 Sep 2025 · 4 likes Coming back to post #51, because the follow-up matters more than the original answer. A vial that will not fully dissolve: check in order: is the diluent genuinely room…
-
Realistic expectations for strength while losing weight quickly Replied, post #15 · Nutrition & Training › Resistance training · 20 Aug 2025 · 16 likes I read post #13 twice before replying, because I had assumed the opposite. Two things before anyone answers the substance. First, the context in the first post is clear…
-
Why fasting instructions for oral semaglutide are not optional advice — does this still… Replied, post #82 · Compounds › Oral incretins · 14 Aug 2025 · 32 likes I read post #80 twice before replying, because I had assumed the opposite. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write…
-
Second pass at: Why this subcategory is stricter about sourcing than most Replied, post #53 · Compounds › Secretagogues & GH axis · 11 Aug 2025 · 0 likes post #52 is right about the mechanism and I think understates the practical bit. Evidence quality in the secretagogue literature is honestly weaker than in the incretin…
-
Immortal time bias in a claims-database study Replied, post #15 · Evidence › Study critique · 7 Aug 2025 · 20 likes This follows post #12 rather than contradicting it. What makes a methodological criticism substantive: it identifies a specific feature of the design that materially…
-
[2026 update] What we do not know about retatrutide, listed explicitly Replied, post #34 · Compounds › Retatrutide · 3 Aug 2025 · 30 likes This follows post #31 rather than contradicting it. Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the…
-
A ten-fold dose error caught before injection — one year on Replied, post #76 · Devices › Syringes & needles · 3 Aug 2025 · 0 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Which panel is worth repeating and which is worth ignoring Replied, post #73 · Clinical › Bloodwork · 31 Jul 2025 · 0 likes Renal function markers: eGFR is estimated, not measured. It depends on creatinine, age, and weight. A small change in creatinine might not mean a real change in kidney…
-
Revisiting: Reading a denial letter as a specification for your appeal Replied, post #57 · Access › Insurance & coverage · 26 Jul 2025 · 20 likes Appeals process: unemotional prose, the criterion quoted verbatim, evidence mapped to it point by point, dates, and nothing else. Describing how the decision affected…
-
Second pass at: Why this subcategory is stricter about sourcing than most Replied, post #5 · Compounds › Secretagogues & GH axis · 22 Jul 2025 · 0 likes IGF-1 as a surrogate: it is a better integrated measure than a spot growth hormone level and it is still a surrogate, with all the caveats that come with surrogates.…
-
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Replied, post #33 · Compounds › Cagrilintide & amylin analogues · 9 Jul 2025 · 15 likes Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that…
-
Domestic fridge temperature mapping: a cheap experiment — what changed since Replied, post #133 · Devices › Cold chain · 30 Jun 2025 · 0 likes Worth separating two things that post #129 runs together. Shipment during summer or to hot climates: consider shipping to a cold-storage facility rather than to home if…
-
Journal club: the CagriSema phase 2 combination paper — a second dataset Replied, post #59 · Evidence › Journal club · 29 Jun 2025 · 0 likes TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.
-
Promotion criteria, and the one that stops most nominations — the long version Replied, post #16 · Documentation › Doc review · 23 Jun 2025 · 0 likes post #15 answers the question as asked. The question underneath it is different. Review date disputes: if a maintained page's review date is approaching and it has not…
-
An emergency department visit, described afterwards Replied, post #24 · Safety › Adverse events · 25 May 2025 · 0 likes Psychological adverse events: mood changes, anxiety, or suicidal ideation warrant discussion with a mental health professional. These are rare but real.
-
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #80 · Sourcing › Independent verification · 11 May 2025 · 5 likes I read post #78 twice before replying, because I had assumed the opposite. Blind sampling: submitting without the laboratory or seller knowing the source removes the…
-
Albumin binding and how it produces a long half-life Replied, post #31 · Pharmacology › Pharmacokinetics · 1 May 2025 · 1 like post #30 answers the question as asked. The question underneath it is different. Individual variation: people vary in how quickly they absorb, distribute, metabolise,…
-
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #40 · Compounds › Retatrutide · 20 Apr 2025 · 0 likes Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make…
-
Second pass at: Retatrutide mass and identity: what a report should show Replied, post #25 · Compounds › Retatrutide · 20 Apr 2025 · 9 likes What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate…
-
Second pass at: Pen dose counters: what a click does and does not guarantee Replied, post #15 · Devices › Pens & autoinjectors · 9 Apr 2025 · 4 likes Needle installation: some pens require a fresh needle for each injection; others have a single needle that stays attached. Check the design of your pen.
-
Requesting a page: what makes a good request Replied, post #24 · Documentation › Wiki requests · 15 Mar 2025 · 0 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
When a preprint is the best available evidence and we say so — a second dataset Replied, post #15 · Evidence › Preprints · 4 Mar 2025 · 0 likes Always label it as a preprint in any discussion. A preprint is not a published trial and it is not settled knowledge. Use it for hypothesis generation and for…
-
[2026 update] New subcategory: rationale and scope Replied, post #131 · Meta › Announcements · 8 Jan 2025 · 6 likes RSS: if you prefer to receive announcements by feed rather than visiting the site, RSS is available for this subcategory.
-
Transporting a vial for a weekend away Replied, post #21 · Practice › Storage & stability · 31 Oct 2024 · 0 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
What a stability-indicating method is and how you demonstrate one — one year on Replied, post #61 · Analytics › Method validation · 28 Oct 2024 · 1 like On post #57 — agreed on the reasoning, with one qualification. Two things before anyone answers the substance. First, the context in the first post is clear and…
-
Revisiting: A staff appointment, and what the role involves Replied, post #3 · Meta › Announcements · 7 Oct 2024 · 18 likes Feedback to announcements: if you have feedback on an announced change (not a question, but your position) post it in the Meta category rather than here.
-
Second pass at: Sodium, potassium and magnesium when intake drops Replied, post #124 · Nutrition & Training › Hydration & electrolytes · 30 Sep 2024 · 1 like Worth separating two things that post #120 runs together. Orthostatic symptoms: dizziness on standing after lying down can indicate dehydration or electrolyte…
-
When a red flag was a misunderstanding, and the retraction Replied, post #2 · Sourcing › Red flags · 12 Aug 2024 · 31 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Guidelines revision: what changed and why Replied, post #123 · Meta › Announcements · 28 Jul 2024 · 4 likes Notifications: watching this subcategory means you receive notifications when announcements are posted. Useful if you want to stay current.
-
The mass-error checker and its intended scope Replied, post #160 · Data & Tools › Calculators · 28 Jul 2024 · 5 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Second pass at: Retatrutide dose escalation in the published trials Replied, post #106 · Compounds › Retatrutide · 23 Jul 2024 · 0 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Spreadsheets: an appreciation Replied, post #28 · Lounge › Off topic · 10 Jun 2024 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…